William Pass, DVM

Over the past 30 years, from the discovery of a fusion rearrangement to the recent promise of LOXO-292, RET targeting has gone from distant concept toward clinical reality.

Researchers remain keenly interested in exploring PIK3CA as an anticancer target in breast cancer.

Rapid progress in the development of BET inhibitors has created a surge of enthusiasm.

Although mutant RAS has proved to be a challenging therapeutic target, recent success with tipifarnib, a biologically active drug known as a farnesyltransferase inhibitor, brings promise for treating solid tumors and hematological malignancies.